India, Feb. 18 -- Sandoz Group Ltd (SDZNY) on Wednesday announced that the U.S. Food and Drug Administration has approved an expanded label for Enzeevu, broadening its use to treat multiple retinal diseases.
The updated approval expands Enzeevu's indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and diabetic macular edema (DME), in addition to its previously approved use for neovascular (wet) age-related macular degeneration (nAMD).
Sandoz said it plans to launch Enzeevu in the U.S. in the fourth quarter of 2026, or earlier.
Published by HT Digital Content Services with permission from RTT News....